Do we need to redefine the advanced stage in Parkinson's disease?

被引:0
|
作者
Sesar, Angel [1 ]
Fernandez-Pajarin, Gustavo [1 ]
Ares, Begona [1 ]
Castro, Alfonso [1 ]
机构
[1] Hosp Clin Univ, Movement Disorder Unit, Neurol Dept, Santiago De Compostela, Spain
来源
REVISTA MEXICANA DE NEUROCIENCIA | 2021年 / 22卷 / 04期
关键词
Parkinson's disease; Advanced stage; Post-advanced stage; Dopaminergic symptoms; Non-dopaminergic symptoms; SYDNEY MULTICENTER; SYMPTOMS;
D O I
10.24875/RMN.20000119
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Identifying the advanced stage in Parkinson's disease ( PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dyskinesia and complex therapeutic regimes, but have also included invalidating non-dopaminergic symptoms, such as dementia, falls or dysphagia. These last problems usually appear in a much later stage of the advanced PD. The key to the definition of advanced PD should be the lack of adequate PD control of both motor and non-motor dopaminergic symptoms. The patient's judgment about the quality of their response to conventional therapy is also critical to establish the advanced stage. The early identification of this phase allows maintaining the patient's functional state whenever appropriate treatments are applied. We should keep the term advanced stage when the dopaminergic symptoms responsive to device-aided therapy are preponderant. When invalidating non-dopaminergic symptoms dominate the clinical picture, the term post-advanced stage could be more suitable.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 50 条
  • [21] Medical treatment of Parkinson's disease in advanced stage
    Jost, W.
    NERVENHEILKUNDE, 2010, 29 (06) : 351 - +
  • [22] Other symptoms of advanced stage Parkinson's disease
    Pollak, P
    Tranchant, C
    REVUE NEUROLOGIQUE, 2000, 156 : 165 - 173
  • [23] Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease?
    Pavese, Nicola
    EXPERIMENTAL NEUROLOGY, 2012, 233 (01) : 118 - 120
  • [24] Cost and Benefit of Accounting Information in Slovakia: Do We Need to Redefine Relevance?
    Tumpach, Milos
    Bastincova, Anna
    EUROPEAN FINANCIAL SYSTEMS 2014, 2014, : 655 - 661
  • [25] Low-temperature sterilization technologies: Do we need to redefine ''sterilization''
    Rutala, WA
    Weber, DJ
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1996, 17 (02): : 87 - 91
  • [26] Attend, consult, involve: do we need to redefine the concept of community engagement?
    Cassetti, Viola
    Lopez-Ruiz, Maria Victoria
    Gallego-Royo, Alba
    Egea-Ronda, Ana
    Gea-Caballero, Vicente
    Ulpiano, Dory Avino Juan
    Cano, Maria Pilar Baraza
    Rodriguez, Esperanza Romero
    GACETA SANITARIA, 2023, 37
  • [27] Has the time come to redefine Parkinson's disease?
    Darweesh, Sirwan K. L.
    Sampaio, Cristina
    Bloem, Bastiaan R.
    LANCET NEUROLOGY, 2024, 23 (02): : 130 - 133
  • [28] Do we need to redefine caring? How about re-finding it? A response to Mochan's Query
    Betts, Clinton E.
    NURSING PHILOSOPHY, 2008, 9 (04) : 288 - 290
  • [29] Where do we stand in the treatment of Parkinson's disease?
    Mizuno, Yoshikuni
    JOURNAL OF NEUROLOGY, 2007, 254 (Suppl 5) : 13 - 18
  • [30] Where do we stand in the treatment of Parkinson's disease?
    Yoshikuni Mizuno
    Journal of Neurology, 2007, 254 : 13 - 18